X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IGV-001 is an autologous biologic-device combination product derived from Imvax’s proprietary Goldspire™ immuno-oncology platform for solid tumors. Currently it is being developed for newly diagnosed glioblastoma.
Lead Product(s): IGV-001,Temozolomide
Therapeutic Area: Oncology Product Name: IGV-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
In the Phase 1b study of IGV-001, multiple efficacy signals were observed including significant improvements in progression-free survival, radiographic evidence of tumor response, and multiple biomarker changes that supported the presence of an immune response.
Lead Product(s): IGV-001,Temozolomide
Therapeutic Area: Oncology Product Name: IGV-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
Study had previously reported a median progression-free survival of 17.1 months in newly diagnosed glioblastoma patients in the highest dose cohort treated with IGV-001, compared with 6.5 months in historical standard-of-care-treated patients (P=0.0025).
Lead Product(s): IGV-001,Temozolomide
Therapeutic Area: Oncology Product Name: IGV-001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
IGV-001 is Imvax’s most advanced product candidate, in development to treat GBM. It has completed a Phase 1a in recurrent glioblastoma and a Phase 1b in newly diagnosed glioblastoma which in total dosed 46 patients.
Lead Product(s): Autologous GBM Cells,IMV-001,Temozolomide
Therapeutic Area: Oncology Product Name: IGV-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
The data from in vitro and in vivo studies highlight the effects of IGV-001 on inducing both innate and adaptive immune responses to tumor cells and point to the potential mechanism behind observed clinical activity for IGV-001 in the treatment of glioblastoma.
Lead Product(s): IGV-001
Therapeutic Area: Oncology Product Name: IGV-001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2021
Details:
Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme, Phase 1 research into additional solid tumor indications and build out of the operational capabilities.
Lead Product(s): IGV-001
Therapeutic Area: Oncology Product Name: IGV-001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: HP WILD Holding AG
Deal Size: $112.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing July 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
